Key regions: Australia, Japan, United States, Germany, Europe
Anti-Coagulants, also known as blood thinners, are a class of drugs that prevent blood clotting, reducing the risk of strokes, heart attacks, and other cardiovascular diseases. In Baltics, the Anti-Coagulants market is witnessing an upward trend due to several factors.
Customer preferences: The customer preferences in the Anti-Coagulants market in Baltics are similar to those in other regions. Patients prefer drugs that are easy to administer, have fewer side effects, and are affordable. The market is dominated by oral anticoagulants, which are more convenient and have fewer side effects than injectable ones. Patients also prefer drugs that require less monitoring and have fewer drug interactions.
Trends in the market: The Anti-Coagulants market in Baltics is witnessing several trends. One of the major trends is the increasing use of direct oral anticoagulants (DOACs) over warfarin, the traditional blood thinner. DOACs have several advantages over warfarin, including fewer side effects, no need for regular monitoring, and fewer drug interactions. Another trend is the increasing use of Anti-Coagulants for the prevention of venous thromboembolism (VTE) in high-risk patients, such as those undergoing surgery or with cancer.
Local special circumstances: Baltics is a region with a high prevalence of cardiovascular diseases, such as hypertension, stroke, and coronary heart disease. This has led to an increased demand for Anti-Coagulants in the region. Additionally, the region has an aging population, which is more susceptible to cardiovascular diseases and requires long-term treatment with Anti-Coagulants.
Underlying macroeconomic factors: Baltics is a region with a growing economy and a stable healthcare system. The region has a high level of healthcare expenditure, which has led to an increased availability of Anti-Coagulants in the market. Additionally, the region has a well-established pharmaceutical industry, which has led to increased competition and lower prices for Anti-Coagulants.In conclusion, the Anti-Coagulants market in Baltics is witnessing an upward trend due to several factors, including increasing use of DOACs, high prevalence of cardiovascular diseases, and a stable healthcare system. The market is expected to continue growing in the coming years, driven by an aging population and increasing demand for preventive healthcare.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
